FOLH1 and prostate carcinoma: The ENZAp trial, a randomized controlled phase 2 trial evaluating [177Lu]Lu-PSMA-617 in addition to enzalutamide in men with high-risk metastatic castration-resistant prostate cancer, was conducted at 15 sites in Australia.